Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,169 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase.
Lin HM, Mak B, Yeung N, Huynh K, Meikle TG, Mellett NA, Kwan EM, Fettke H, Tran B, Davis ID, Mahon KL, Zhang A, Stockler MR, Briscoe K, Marx G, Crumbaker M, Stricker PD, Du P, Yu J, Jia S, Scheinberg T, Fitzpatrick M, Bonnitcha P, Sullivan DR, Joshua AM, Azad AA, Butler LM, Meikle PJ, Horvath LG. Lin HM, et al. Among authors: fitzpatrick m. EBioMedicine. 2021 Oct;72:103625. doi: 10.1016/j.ebiom.2021.103625. Epub 2021 Oct 14. EBioMedicine. 2021. PMID: 34656931 Free PMC article.
PCPro: a clinically accessible, circulating lipid biomarker signature for poor-prognosis metastatic prostate cancer.
Scheinberg T, Lin HM, Fitzpatrick M, Azad AA, Bonnitcha P, Davies A, Heller G, Huynh K, Mak B, Mahon K, Sullivan D, Meikle PJ, Horvath LG. Scheinberg T, et al. Among authors: fitzpatrick m. Prostate Cancer Prostatic Dis. 2024 Mar;27(1):136-143. doi: 10.1038/s41391-023-00666-2. Epub 2023 May 5. Prostate Cancer Prostatic Dis. 2024. PMID: 37147359 Free PMC article.
Evolocumab in metastatic castration-resistant prostate cancer: study protocol for a single-arm, phase II trial, and initial experience with use of a validated lipid biomarker to direct therapy.
Mellor R, Ardolino L, Scheinberg T, Fitzpatrick M, Lin HM, Bonnitcha P, Sullivan D, Meikle PJ, Stockler MR, Moujaber T, Joshua A, Horvath L. Mellor R, et al. Among authors: fitzpatrick m. Ther Adv Med Oncol. 2024 Dec 16;16:17588359241307814. doi: 10.1177/17588359241307814. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 39691585 Free PMC article.
1,169 results